<DOC>
	<DOCNO>NCT02086071</DOCNO>
	<brief_summary>Feasibility new biological histological sample progression patient advance metastatic Non Small Cell Lung Cancer ( NSCLC ) . A recent paper Pr Sequist coll . depict resistance mechanism Thréonine790Methionine ( T890M ) mutation oncogene cMet ( CMet ) amplification . Re-biopsies show 14 % case transition NSCLC Small Cells Lung Cancer ( SCLC ) . In 3 patient , resistance mechanism disappear become sensitive Tyrosine Kinase Inhibitors ( TKIs ) . It mandatory good description natural history disease . This study conduct Groupe Français de Pneumo Cancérologie ( GFPC ) 100 patient 18 Months . Each center define re-biopsies possible explain .</brief_summary>
	<brief_title>Feasibility Biopsies Progression</brief_title>
	<detailed_description>ABSTRACT PROMOTOR GFPC MAIN INVESTIGATORS Pr Vergnenegre Alain , Dr Dujon Cécile , Pr Rosell Rafael TITLE Feasibility new biological histological sample progression patient advance metastatic Non Small Cell Lung Cancer ( NSCLC ) JUSTIFICATION / BACKGROUND In NSCLC , recent progress reach , good outcome term survival without relapse , response rate , improvement Qualify Life ( QoL ) . In detail , patient mutation Epidermal Growth Factor Receptor ( EGF-R ) sensitive tyrosine kinase inhibitor ( TKIs ) . 1 . Patients EGF-R mutation Response disease control frequently achieve long period time , majority case , resistance appear around period 12 month diagnosis . One major resistance mechanism onset T790M mutation , induces non sensitivity TKIs . At opposite , recent paper depict , free interval , resistant tumor responder second phase TKIs ] . The type mutation different consequence disease evolution . A recent paper Pr . Sequist coll . depict resistance mechanism mutation T790M oncogene cMet ( CMet ) amplification . Re-biopsies show 14 % case transition NSCLC SCLC . In 3 patient , resistance mechanism disappear become sensitive TKIs . It mandatory good description natural history disease . 2 . Patients without EGF-R mutation The knowledge genetic characteristic currently need perform inclusion research protocol . TRIAL DESIGN Translational study iterative biopsy . OUTCOMES CRITERIA Principal outcome Feasibility re-biopsies Secondary outcomes - analysis type resistance , - time metastasis desappearance - correlation disease management - biological history disease . INCLUSION CRITERIA All patient 18 year old , advanced metastatic NSCLC . NON INCLUSION CRITERIA - SCLC , neuroendocrine carcinoma , - Patients judicial protection deprive liberty PROCEDURES A paper CRF record data : - Patients 's characteristic , - Tumor Node Metastasis classification ( TNM ) stage , - Number metastasis location diagnosis , - First line treatment : surgery , radiotherapy , chemotherapy , - Date EGF-R status response , - Date relapse , - Type procedure , - Treatment second third line management NUMBER OF PATIENTS 100 patient NUMBER OF CENTRES 20 centre DURATION 18 month PRACTICAL ORGANIZATION IN EACH CENTER Each center define re-biopsies possible ( explain ) . Some localisation difficult biopsy like bone metastasis deep brain metastasis . A bronchial fiberscopy systematically perform search endoluminal lesion , could allow 3 5 tissue sample . When possible , liver , adrenal gland , superficial brain metastasis analyse relapse . 1 . For patient EGF-R mutation The sample prepare usual technic center . The corresponding slide send spanish laboratory ( Pr R Rosell , Badalona hospital ) A comparison patient impossible re-biopsies final patient group perform . 2 . For patient without EGF-R mutation usual practice use biological platform BIOLOGICAL PROCEDURES 1 . Patients EGF-R mutation Biological marker analysis coordinate Catalan Institute Oncology . 2 . Patients without EGF-R mutation : usual biological analysis perform local platform . STATISTICAL ANALYSES A description item perform term frequence , range , mean median . Correlation biological marker assess non parametric test Wilcoxon Mann-Whitney . POSSIBLE APPLICATIONS - good knowledge resistance mechanisms EGF-R mutate patient - good knowledge genetical molecular history diseases - well management accord biological change evolution</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>All patient 18 year old advance metastatic NSCLC progression one treatment chemotherapy . SCLC , neuroendocrine carcinoma , Patients judicial protection deprive liberty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>REBIOP re-biopsies advance metastatic NSCLC</keyword>
</DOC>